Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Phio Pharmaceuticals Corp.PHIO · Entity 7889 | Chief Financial Officer | September 28, 2026 | September 29, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Phio Pharmaceuticals Corp.
Report date September 28, 2026 · Filed September 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $.0001 par valueSEC Table I · non-derivative | Direct | 189,112 |
Reported balance
After 2026-09-28 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-09-28 · Grant · Acquired 108,000 · Balance 189,112 F1: Represents shares underlying a restricted stock unit, which shares will vest on the first annual anniversary of the grant. F2: Includes shares of common stock underlying unvested restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares underlying a restricted stock unit, which shares will vest on the first annual anniversary of the grant.
F2: Includes shares of common stock underlying unvested restricted stock units.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 28, 2026 Filed Sep 29, 2026 20:01 UTC | Phio Pharmaceuticals Corp. PHIO · Entity 7889 | GrantCommon Stock, $.0001 par value | 108,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001683168-26-007481 · ownership.xml · nonDerivative · entry 1 Carson Lisa Cabott · CIK 0002073513 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 189,112 F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest on the first annual anniversary of the grant. F2 · balance_after: Includes shares of common stock underlying unvested restricted stock units. Read SEC document |
| September 11, 2026 Filed Sep 15, 2026 20:00 UTC | Phio Pharmaceuticals Corp. PHIO · Entity 7889 | Tax withholdingCommon Stock, $.0001 par value | 12,888 | $1.03 | $13,274.64 |
DisclosureSEC source: 0001683168-26-007158 · ownership.xml · nonDerivative · entry 1 Carson Lisa Cabott · CIK 0002073513 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,112 F1 · kind: The transaction represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting of restricted stock units. No shares were sold. F2 · balance_after: Includes shares of common stock underlying unvested restricted stock units. Read SEC document |
| February 05, 2026 Filed Feb 6, 2026 07:58 UTC | Phio Pharmaceuticals Corp. PHIO · Entity 7889 | GrantCommon Stock, $.0001 par value | 47,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001683168-26-000807 · ownership.xml · nonDerivative · entry 1 Carson Lisa Cabott · CIK 0002073513 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 94,000 F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest on the first annual anniversary of the grant. F2 · balance_after: Includes shares of common stock underlying unvested restricted stock units. Read SEC document |
| September 11, 2025 Filed Sep 15, 2025 08:28 UTC | Phio Pharmaceuticals Corp. PHIO · Entity 7889 | GrantCommon Stock, $.0001 par value | 47,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001683168-25-006956 · ownership.xml · nonDerivative · entry 1 Carson Lisa Cabott · CIK 0002073513 · VP, Finance and Administration 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,000 F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest on the first annual anniversary of the grant. F2 · balance_after: Includes shares of common stock underlying unvested restricted stock units. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.